Cambodia on verge of achieving malaria-free goal: PM Hun
In a message to mark the National Malaria Day on Friday, he said the Southeast Asian country reported only 355 malaria cases in 2024, a significant drop of 75 per cent compared to 2023.
The prime minister added that the kingdom had reported zero deaths from the disease since 2018 and no local Plasmodium Falciparum cases since 2024.
"Cambodia is on the verge of achieving a malaria-free goal by the end of 2025," Hun Manet said, urging all stakeholders to continue to support the country to achieve the target.
Huy Rekol, director of the National Center for Parasitology, Entomology and Malaria Control, said malaria diagnostic tests and treatments have been highly effective in Cambodia, with Artesunate/Mefloquine, or ASMQ, being 100 per cent safe and efficacious against malaria, Xinhua news agency reported.
"This progress has put Cambodia in the category of successful countries in eliminating malaria," he told Xinhua.
Malaria is a mosquito-borne infectious disease that is typically found in forest and mountainous provinces, especially during rainy seasons.
To avoid being bitten by malaria-carrying mosquitoes, Rekol advises people living in malaria-risk areas to sleep under insecticide-treated mosquito nets at all times.
Symptoms can be mild or life-threatening. Mild symptoms are fever, chills and headache. Severe symptoms include fatigue, confusion, seizures, and difficulty breathing.
Infants, children under 5 years, pregnant women and girls, travellers and people with HIV or AIDS are at higher risk of severe infection.
Malaria can be prevented by avoiding mosquito bites and with medicines. Treatments can stop mild cases from getting worse.
Malaria mostly spreads to people through the bites of some infected female Anopheles mosquitoes. Blood transfusion and contaminated needles may also transmit malaria.
The first symptoms may be mild, similar to many febrile illnesses, and difficulty to recognise as malaria.
Left untreated, P. falciparum malaria can progress to severe illness and death within 24 hours.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
21 hours ago
- Hans India
Four dead after cholera outbreak hits Chad refugee camp
N'Djamena: At least four people have died following a cholera outbreak in a refugee camp in eastern Chad, the country's Health Ministry said in a statement on Friday. A total of 42 suspected cases have been recorded in the Dougui refugee camp in the Ouara department of Ouaddai province, the statement said, adding that samples have been collected and sent to the capital, N'Djamena, for confirmatory testing. Authorities have called for vigilance and strict adherence to hygiene measures to slow the spread of the disease. Dougui refugee camp hosts approximately 20,000 Sudanese refugees, Xinhua news agency reported. In June, the World Health Organisation (WHO) warned that cholera cases in Sudan are set to rise and could spread to neighbouring countries, including Chad, which hosts hundreds of thousands of refugees from Sudan's civil war, in crowded conditions. According to the WHO, cholera is an acute diarrhoeal infection caused by consuming food or water contaminated with the bacterium Vibrio cholerae. It is a global public health threat and indicates inequality and a lack of social and economic development. Access to safe water, basic sanitation and hygiene is essential to prevent cholera and other waterborne diseases. Most people with cholera have mild or moderate diarrhoea and can be treated with oral rehydration solution (ORS). However, the disease can progress rapidly, so starting treatment quickly is vital to save lives. Patients with severe disease need intravenous fluids, ORS, and antibiotics. Countries need strong epidemiological and laboratory surveillance to swiftly detect and monitor outbreaks and guide responses. Cholera outbreaks occur regularly in some countries. In others, they are less frequent, and it may be years between outbreaks. Cholera is linked to limited access to safe water, basic sanitation facilities and poor hygiene practices. This may be due to conflict, population displacement, climate events like cyclones, floods or drought, and lack of investment in maintaining and improving WASH services and infrastructure. The number of cholera cases reported to the WHO has continued to rise in recent years. In 2023, 535,321 cases and 4007 deaths were reported to the WHO from 45 countries. The discrepancy between these figures and the numbers estimated by researchers is likely due to limited surveillance systems and cases not being recorded out of fear of repercussions for trade and tourism.
Hans India
21 hours ago
- Hans India
Uganda sees nearly 70 pc drop in mpox cases over four weeks
Kampala: Uganda has recorded a 69.9 per cent decline in mpox cases over the past four weeks, according to a new situation report released on Friday by the Ministry of Health. The report shows that weekly reported cases dropped consistently from 233 in epidemiological week 26 to 173 in week 27, 108 in week 28, and 70 in week 29. "This corresponds to a 25.8 per cent decrease from week 26 to 27, 37.6 per cent from week 27 to 28, and 35.2 per cent from week 28 to 29," the report noted. "Overall, there was a 69.9 per cent cumulative reduction in incident cases reported over the four-week period." Since the outbreak was declared in August last year, Uganda has recorded 7,648 confirmed mpox cases and 48 deaths. Health authorities have stepped up vaccination, surveillance, case management, and public awareness initiatives to curb the spread of the virus, Xinhua news agency reported. According to the World Health Organisation, Mpox is an infectious disease that can cause a painful rash, enlarged lymph nodes, fever, headache, muscle aches, back pain and low energy. Most people fully recover, but some get very sick. Mpox spreads from person to person mainly through close contact with someone who has mpox, including members of a household. Close contact includes skin-to-skin (such as touching or sex) and mouth-to-mouth or mouth-to-skin contact (such as kissing), and it can also include being face-to-face with someone who has mpox (such as talking or breathing close to one another, which can generate infectious respiratory particles). People with multiple sexual partners are at higher risk of acquiring mpox. People can also contract mpox from contaminated objects such as clothing or linen, through needle injuries in health care, or in community settings such as tattoo parlours. During pregnancy or birth, the virus may be passed to the baby. Contracting mpox during pregnancy can be dangerous for the fetus or newborn infant and can lead to loss of the pregnancy, stillbirth, death of the newborn, or complications for the parent. The monkeypox virus was discovered in Denmark (1958) in monkeys kept for research. The first reported human case of mpox was a nine-month-old boy in the Democratic Republic of the Congo (1970). Following the eradication of smallpox in 1980 and the end of smallpox vaccination worldwide, mpox steadily emerged in central, east and west Africa. Since then, mpox has been reported sporadically in central and east Africa (clade I) and west Africa (clade II).
Indian Express
2 days ago
- Indian Express
How new ICMR vaccine gives new hope in fight against malaria
The Indian Council of Medical Research (ICMR) has announced a promising candidate vaccine for malaria, which it will now further develop, test and manufacture for commercial purposes in partnership with private companies. Known as AdFalciVax, the vaccine mainly targets two parts of Plasmodium falciparum, a pathogen that is the most common source of malaria in humans. In India, however, the disease is caused by Plasmodium vivax against which AdFalciVax is ineffective. Malaria is a parasitic infection transmitted by mosquitoes, typically causing symptoms such as fever, chills, night sweats, nausea, vomiting, and diarrhoea. In some cases, it can lead to severe complications such as seizures, fluid in the lungs, organ damage, and death. Having claimed millions of lives, malaria has been one of the deadliest diseases in human history. Currently, the disease kills about four lakh people annually, according to World Health Organization (WHO) figures. Malaria is most endemic in Africa — Nigeria, Congo, Tanzania, Mozambique, Niger, and Burkina Faso together account for more than half the yearly deaths. The disease is also present in India, although malaria deaths have sharply reduced in the country in recent years. According to the National Vector Borne Disease Control Programme (NVBDCP), reported malaria deaths stood at 1,151in 1995, and came down to only 93 in 2020 and 83 in 2022. Note that these figures are much lower than the numbers provided annually by the WHO. The organisation's 'World Malaria Report' says there were 5,511 deaths due to the disease in India in 2022. This discrepancy is due to WHO providing estimates and NVBDCP providing only the number of confirmed deaths, which may not have been officially reported. To combat malaria, scientists have been working to develop a vaccine for decades but with limited success. Recently, two vaccines—RTS,S and R21—were approved for use, but their efficacy, at 75%, is quite low. That's why the announcement about ICMR's candidate vaccine has given new hope in the fight against the disease. AdFalciVax is a chimeric recombinant vaccine — a type of vaccine that uses different parts of the genes of a pathogen (in this case, Plasmodium) to create target proteins that trigger an immune response after being injected. AdFalciVax uses two types of target proteins to prevent the spread of infection in two different ways. n It uses the circumsporozoite protein (CSP) to prevent infection in the person who has been immunised. The CSP is produced during the sporozoite stage (when a parasite can infect a new host) and the liver stage (when a parasite enters liver cells, multiplies, and then infects red blood cells) of the parasite. Subhash Singh, project manager for development of the vaccine at the ICMR-Regional Medical Research Centre, Bhubaneswar, told The Indian Express: 'Any immune response generated against these stages protects the immunised person from getting the infection.' n The vaccine also uses the Pro6C protein, a fusion of parts of two different proteins — Pfs230 and Pfs48/45 — produced by Plasmodium falciparum. This protein prevents the spread of infection in the community. 'The Pro6C protein… stops further spread of the disease by disrupting the lifecycle of the pathogen. It disrupts the development of the parasite in the midgut of a mosquito preventing further transmission,' Singh said. Unlike AdFalciVax, RTS,S and R21 only use the CSP protein, and can prevent infection only in vaccinated persons. Unlike AdFalciVax, RTS,S and R21 vaccines also do not use full-length CSP proteins. This is why the ICMR's candidate vaccine is 'likely to produce a stronger immune response and better protect against infection,' according to Singh. Researchers have found that AdFalciVax provided more than 90% protection against infection in mice. The candidate vaccine has yet to undergo rigorous human trials, and the preliminary results have been obtained only through testing on animals. Studies have also suggested that AdFalciVax produces an immune response that may last longer than that produced by the other two vaccines. Singh said: 'One of the challenges of existing vaccines is that the immune response is short-lived. People need a fifth booster shot even after four primary doses. We do not know how this will work in humans, but preliminary indications show that three doses of the ICMR candidate vaccine produced robust protection against infection in mice for more than three months. This roughly translates to a decade in human life.' AdFalciVax also contains an adjuvant — a substance used in vaccines to boost the body's immune response against the targeted disease — called alum. Singh says the use of alum is beneficial as it does not pose a risk of causing chronic inflammation, unlike adjuvants such as AS01 and Matrix M, which are used in RTS,S and R21. Alum is also known to be reliable, and has been used in numerous vaccines used in childhood immunisation programs over the years. Another advantage is that alum in AdFalciVax can remain stable at room temperature for at least nine months, according to initial studies. This might make it possible to 'transport the vaccines without maintaining the cold chain,' Singh said. The ICMR wants to partner with a company that can further develop its candidate vaccine, carry out human clinical trials, and scale up for commercial production. Although the ICMR will share the technology of developing AdFalciVax with the chosen company, it will continue to hold the intellectual property rights. Any intellectual property rights generated during the collaboration will be held jointly by the ICMR and the company. The ICMR will also earn 2% royalty on any sales of the vaccine. Authors from both the company and the ICMR will be credited in any research papers generated, and all data will be jointly owned.
